Role of lipoprotein(a) in predicting the severity of new on-set coronary artery disease in type 2 diabetics: A Gensini score evaluation

Diabetes and Vascular Disease Research

Volumn 12, Issue 4, 2015, Pages 258-264

  Chen, Juan ^a,b   Zhang, Yan ^a   Liu, Jun ^b   Chen, Man Hua ^b   Guo, Yuan Lin ^a   Zhu, Cheng Gang ^a   Xu, Rui Xia ^a   Dong, Qian ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

^b CENTRAL HOSPITAL OF WUHAN   (China)

Author keywords

coronary artery disease; Gensini score; Lipoprotein(a); type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DATA ANALYSIS; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; GENSINI SCORE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CODING; PREDICTION; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ANGIOCARDIOGRAPHY; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; COMPLICATION; CORONARY ARTERY OBSTRUCTION; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSPECTIVE STUDY; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY STENOSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIPOPROTEIN(A); LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES; YOUNG ADULT;

EID: 84936994446     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164115579004     Document Type: Article

References (29)

1. Craig WY, Neveux LM, Palomaki GE,. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998; 44: 2301-2306.
2. Kamstrup PR,. Lipoprotein(a) and ischemic heart disease: a causal association? A review. Atherosclerosis 2010; 211: 15-23.
3. Wood RJ, Volek JS, Davis SR,. Effects of a carbohydrate-restricted diet on emerging plasma markers for cardiovascular disease. Nutr Metab 2006; 3: 19.
4. Sofi F, Fatini C, Sticchi E,. Fish intake and LPA 93C>T polymorphism: gene-environment interaction in modulating lipoprotein (a) concentrations. Atherosclerosis 2007; 195: e147-e154.
5. Carlson LA, Hamsten A, Asplund A,. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989; 226: 271-276.
6. Shewmon DA, Stock JL, Rosen CJ,. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994; 14: 1586-1593.
7. Nordestgaard BG, Chapman MJ, Ray K,.; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-2853.
8. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R,. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301: 2331-2339.
9. Suk Danik J, Rifai N, Buring JE,. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006; 296: 1363-1370.
10. Erqou S, Kaptoge S, Perry PL,. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-423.
11. Boroumand MA, Rekabi V, Davoodi G,. Correlation between lipoprotein(a) serum concentration and severity of coronary artery stenosis in an Iranian population according to Gensini score. Clin Biochem 2008; 41: 117-120.
12. Watts GF, ap Gwilym RM, Mazurkiewicz J,. Independent correlation between plasma lipoprotein(a) and angiographic coronary artery disease in NIDDM. Diabetes Care 1995; 18: 234-236.
13. Gazzaruso C, Bruno R, Pujia A,. Lipoprotein(a), apolipoprotein(a) polymorphism and coronary atherosclerosis severity in type 2 diabetic patients. Int J Cardiol 2006; 108: 354-358.
14. Umahara T, Uchihara T, Yamada S,. Differential expression of oxidized/native lipoprotein(a) and plasminogen in human carotid and cerebral artery plaques. Atherosclerosis 2011; 215: 392-398.
15. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG,. Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol 2012; 32: 1732-1741.
16. Caplice NM, Panetta C, Peterson TE,. Lipoprotein(a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001; 98: 2980-2987.
17. Pedreno J, Fernandez R, Ballester A,. Lack of association of serum lipoprotein(a) levels with type 2 diabetes mellitus in patients with angiographically defined coronary artery disease. Int J Cardiol 2000; 74: 159-167.
18. Sullivan DR, Marwick TH, Freedman SB,. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J 1990; 119: 1262-1267.
19. Boffa MB, Koschinsky ML,. Screening for and management of elevated Lp(a). Curr Cardiol Rep 2013; 15: 417.
20. Gouni-Berthold I1, Berthold HK,. Lipoprotein(a): current perspectives. Curr Vasc Pharmacol 2011; 9: 682-692.
21. Yazici M, Demircan S, Ibrahimli F,. The importance of lipoprotein(a) in pathogenesis of the high risk unstable angina. Anadolu Kardiyol Derg 2006; 6: 13-17.
22. Enkhmaa B, Anuurad E, Zhang W,. Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans. Atherosclerosis 2014; 235: 223-229.
23. Langsted A, Kamstrup PR, Nordestgaard BG,. Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk. Atherosclerosis 2014; 234: 95-101.
24. Lamon-Fava S, Marcovina SM, Albers JJ,. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res 2011; 52: 1181-1187.
25. Shai I, Rimm EB, Hankinson SE,. Lipoprotein(a) and coronary heart disease among women: beyond a cholesterol carrier? Eur Heart J 2005; 26: 1633-1639.
26. Momiyama Y, Ohmori R, Fayad ZA,. Associations between serum lipoprotein(a) levels and the severity of coronary and aortic atherosclerosis. Atherosclerosis 2012; 222: 241-244.
27. Sposito AC, Mansur AP, Maranhão RC,. Triglyceride and lipoprotein(a) are markers of coronary artery disease severity among postmenopausal women. Maturitas 2001; 39: 203-208.
28. Kronenberg F, Kuen E, Ritz E,. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000; 11: 105-115.
29. Jenkins AJ, Steele JS, Janus ED,. Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1992; 35: 1055-1059.